Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

Share Price is delayed by 15 minutes
Get Live Data
3.25    0.00 (0.00%)
Bid:
3.00
Ask:
3.50
Spread: 0.50 (16.667%)
Market Cap: £1.03m
SNT Live PriceLast checked at - London Stock Exchange

Intraday Sabien Tech. Share Chart

Related Party Funding

20 Aug 2024 07:00

RNS Number : 9959A
Sabien Technology Group PLC
20 August 2024
Β 

20 August 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310.

Sabien Technology Group plc

("Sabien" or the "Company" or the "Group")

Related Party Funding

Sabien Technology Group plc (AIM: SNT), a leader in Green Aggregation Strategy, today provides an update regarding the related party funding announced in the trading update on 8 July 2024.

The Board of Sabien have agreed the following funding arrangements with Richard Parris' family office - Parris Group Limited ("PGL") - which will ensure that the Group has sufficient working capital for the next 12 months without the need for a placing, based on current sales forecasts.

1. Remainder of PGL Loan facility announced 19 February 2024

The loan facility announced on 19 February 2024 has Β£100,000 remaining available to be drawn down. It is expected this will be required within the next 12 months.

2. PGL wholesale stock facility

PGL has agreed to provide a facility whereby it will buy Sabien M2G and M2G Cloud Connect and related stock in bulk. PGL will then resell that stock to Sabien in the smaller quantities required to meet Sabien customer demand. PGL will take a 20% wholesaler mark up on the stock and be paid by Sabien once cash is collected from the end customer.

3. PGL R&D and IT support agreement

PGL has agreed to take over responsibility for the remaining software and hardware development required to commercialise the final stage in the M2G Cloud Connect development and for the Group IT support function. PGL will provide these services via its digital trust solution subsidiary: Aretiico Group Plc. PGL will take a 5% royalty on M2G sales and be paid by Sabien once cash is collected from the end customer.

4. Issue of equity to settle outstanding Board remuneration, broker fees and other liabilities

Richard Parris and Ed Sutcliffe in their capacity as directors of Sabien have agreed to accept settlement of Β£61,936 outstanding Director remuneration (the "Director Remuneration"); the Company's broker has agreed to accept settlement for Β£40,000 of broker fees; and Β£25,000 of other liabilities will be settled via the issue of new ordinary shares ("New Shares") in Sabien. New Shares will be issued at the average share price for the five days preceding this announcement of 9.175 pence.

The following amounts will be settled in new ordinary shares with fractional entitlements rounded down:

DIRECTOR

COUNTERPARTY

OUTSTANDING REMUNERATION

Β£

PRICE PER NEW ORDINARY SHARE PENCE

NEW ORDINARY SHARES ISSUED

TOTAL BENEFICIAL INTEREST POST ISSUE

Edward Sutcliffe

TVI Group Limited

16,936

9.175

184,589

184,589

Richard Parris

Parris Group Limited

45,000

9.175

490,463

5,571,923

61,936

675,052

Any VAT payable on the fees will be paid in cash.

Application will be made for the 435,967 of the New Shares relating to the Β£40,000 of broker fees to be admitted to trading on AIM and admission is expected to become effective at 8.00 a.m. on 26 August 2024 ("Admission").

Following Admission, the Company will have 23,631,135 Ordinary Shares in issue, each share carrying the right to one vote. The Company does not hold any Ordinary Shares in Treasury. Therefore, following Admission, the figure of 23,631,135 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The 893,035 New Shares relating to the Β£61,936 Directors' remuneration and Β£25,000 other liabilities will be subject to shareholder approval at the next Annual General Meeting, expected to be held in November 2024 or early December 2024.

Related party transactions

Since Parris Group Limited is a company controlled by Richard Parris, a director of the Company, the PGL wholesale stock facility and the PGL R&D IT support agreement each constitute a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. Accordingly, the Independent Directors being Ed Sutcliffe, Charles Goodfellow and Ranald McGregor-Smith consider, having consulted with the Company's nominated adviser, Allenby Capital Limited, that the terms of the Transactions are fair and reasonable insofar as Sabien's shareholders are concerned.

Since Richard Parris and Ed Sutcliffe are directors of the Company, the issue of New Shares to settle the Director Remuneration each constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. Accordingly, the Independent Directors being Charles Goodfellow and Ranald McGregor- Smith consider, having consulted with the Company's nominated adviser, Allenby Capital Limited, that the terms of the Transactions are fair and reasonable insofar as Sabien's shareholders are concerned.

Executive Chairman's Comments

Richard Parris, Executive Chairman, commented:

"The related party funding package demonstrates ongoing confidence and commitment from the Sabien Board and my interests. It also provides Sabien with the necessary working capital to continue with its growth plans without unduly diluting shareholders in a difficult funding environment. The related party funding package aligns stock and R&D requirements with cash inflows from customers and provides security on the successful completion of the commercialisation of the M2G Cloud Connect product."

Β 

For Further Information:

Sabien Technology Group plc

Richard Parris, Executive Chairman

Β 

Β 

Β 

+44 20 7993 3700

investors@sabien.comΒ 

Allenby Capital LimitedΒ (Nominated Adviser)

John DepasqualeΒ /Β Nick Harriss / Vivek BhardwajΒ 

Β 

Β 

+44 203 328 5656

Β 

Peterhouse Capital LimitedΒ (Broker)

Duncan VaseyΒ /Β Lucy WilliamsΒ 

Β 

Β 

+44 207 469 0930

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCGPUMURUPCGMB
Date   Source Headline
11th Jun 20267:00 amRNSIssue of shares to directors & broker
2nd Jun 20267:00 amRNSProposed balance sheet strengthening & M2G update
29th May 20265:00 pmRNSTotal Voting Rights
21st May 20267:00 amRNSProposed Commercial Partnership & Investment
20th May 20266:22 pmRNSSettlement of Historical Contract
31st Mar 20267:00 amRNSHalf-year Report for the 6 months to 31 Dec 2025
10th Feb 20267:00 amRNSDirector/PDMR Shareholding
16th Jan 20265:30 pmRNSHolding(s) in Company
22nd Dec 202512:02 pmRNSUpdate on Funding and Strategic Arrangements
22nd Dec 202512:02 pmRNSUpdate on Funding and Strategic Arrangements
9th Dec 20251:20 pmRNSResult of Annual General Meeting
9th Dec 20257:00 amRNSAGM Statement & Trading Update
19th Nov 20257:00 amRNSProposed Strategic Agreement with COF
13th Nov 20257:00 amRNSFinal Results for the Year Ended 30 June 2025
10th Nov 20257:00 amRNSNew Factoring Facility
5th Nov 202512:01 pmRNSAppointment of Corporate Broker
2nd Oct 202512:06 pmRNSFurther update on Sabien, b.grn & related matters
19th Sep 20257:00 amRNSTrading Update
31st Jul 20254:59 pmRNSTotal Voting Rights
8th Jul 20257:00 amRNSYear End Trading Update
30th Jun 20252:53 pmRNSIssue of shares to directors
23rd Jun 20254:28 pmRNSHolding(s) in Company
17th Mar 20257:00 amRNSHalf-year Report for the 6 months to 31 Dec 2024
6th Feb 202511:43 amRNSUpdate in relation to Aeristech Limited
27th Jan 20257:00 amRNSTrading update - acceleration of new M2G orders
31st Dec 202412:30 pmRNSTotal Voting Rights
19th Dec 202410:51 amRNSResult of Annual General Meeting
19th Dec 20247:00 amRNSUpdate on US Waste Plastics to Oil Project
28th Nov 20247:00 amRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSIssue of shares to non-executive directors
18th Nov 20247:00 amRNSFinal Results & Annual Report & Accounts for 2024
11th Nov 20247:00 amRNSNew M2G Cloud Connection System Order
17th Oct 20247:00 amRNSUpdate on US Waste Plastics to Oil Project
30th Sep 20245:00 pmRNSTotal Voting Rights
26th Sep 20244:21 pmRNSDirector/PDMR Shareholding
19th Sep 20241:00 pmRNSHolding(s) in Company
4th Sep 20245:30 pmRNSAdmission of New Shares & Total Voting Rights
29th Aug 20244:00 pmRNSUpdate on Admission of New Ordinary Shares
20th Aug 20247:00 amRNSRelated Party Funding
8th Jul 20248:15 amRNSTrading Statement
28th Mar 20242:30 pmRNSDirector/PDMR Shareholding
8th Mar 20247:00 amRNSHolding(s) in Company
6th Mar 20247:00 amRNSHolding(s) in Company
5th Mar 202411:52 amRNSHolding(s) in Company
29th Feb 20245:00 pmRNSTotal Voting Rights
21st Feb 202411:27 amRNSResult of Broker Option, Issue of Equity and TVR
20th Feb 20243:45 pmRNSDirector/PDMR Shareholding
19th Feb 20247:45 amRNSPlacement and Broker Option
19th Feb 20247:30 amRNSHalf-year Report for the 6 months to 31 Dec 2023
7th Feb 20247:00 amRNSNew system installed at Hampton Court Palace

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.